Clinical case report
Considerable improvement of severe and difficult-to-treat obsessive-compulsive disorder with comorbid depression under treatment with esketamine and concomitant psychotherapy
Bibliographic Data
| ID | 15529678 |
|---|---|
| Authors | Alexander Kaltenboeck (0000-0001-9632-0823, Medical University of Vienna, corresponding author), Elisa Foerster (Medical University of Vienna), Sabrina Strafner (Vienna General Hospital), Ulrike Demal (Medical University of Vienna), Nilufar Mossaheb (0000-0002-7339-7219, Medical University of Vienna), Fabian Friedrich (0000-0003-2219-9631, Medical University of Vienna) |
| Year | 2023 |
| Volume | 14 |
| Pages | 1291077-1291077 |
| Publication date | 2023-11-28 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2023.1291077 |
| PMID | 38090708 |
| OpenAlex | W4389095860 |
| Language | EN |
| References cited | 16 |
A 28-year-old man was admitted to our psychiatric ward with severe obsessive-compulsive disorder (OCD) and comorbid depression. At intake, obsessive-compulsive symptoms were present most time of the day and were related to an intense fear of causing interpersonal misunderstandings. Various treatment attempts, including cognitive-behavioural therapy (CBT) with exposure and response prevention (ERP), selective serotonin reuptake inhibitors, clomipramine, and add-on antipsychotics were either ineffective and/or were not tolerated, and the patient's condition worsened progressively. Following an in-depth multidisciplinary team discussion and a shared decision-making process, an off-label treatment trial with esketamine and concomitant psychotherapy was started. The patient received 10 esketamine + psychotherapy sessions over a period of about 2 months, followed by two maintenance sessions in about 3-week intervals. After this, he was discharged into regular outpatient care where he continued to receive maintenance esketamine treatment every 4-6 weeks and, independent of this, individual CBT. Following the establishment of esketamine with concurrent psychotherapy, the patient exhibited a remarkable clinical improvement. Obsessive-compulsive symptoms showed a clear and sustained response (Y-BOCS before treatment >35, Y-BOCS at week 8 = 23, Y-BOCS at week 26 = 14). Paralleling this, depressive symptoms also decreased (MADRS before treatment = 47, MADRS at week 9 = 12, MADRS at week 26 = 3). At a naturalistic follow-up at week 66, obsessive-compulsive symptoms were still mild (Y-BOCS = 13), and depression was still in remission (MADRS < 6). This clinical case suggests that (es)ketamine plus concomitant psychotherapy may hold promise as a therapeutic strategy for difficult-to-treat OCD and depression and its full clinical potential should be evaluated in more comprehensive future studies
Clomipramine · Cognition · Concomitant · Depression (economics · Interpersonal psychotherapy · Ketamine · Major depressive disorder · Psychiatry · Psychotherapist · Randomized controlled trial · Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes · Medicine · Obsessive-Compulsive Spectrum Disorders · Psychology · Treatment of Major Depression · Internal Medicine
| Highly cited | No |
|---|